In today's market update, the USD-ZAR gapped higher in intraday trade yesterday as harsher domestic restrictions announced the previous evening weighed on the local unit.
4 reading min
29 Jun 2021
Non-farm payrolls y/y: Q1
Analysis: The recovery in non-agriculture-based jobs from the Q2 low has so far been sluggish, due to numerous industries and businesses still reeling from the impacts of the pandemic. Some support, however, has been offered by the better-than-expected economic growth from Q3 2020 onwards, but the uncertainty around the pandemic continues to undermine conditions supportive of job employment. This suggests that job shedding would have persisted in Q1, albeit at a more gradual pace. Readers should be mindful that the Q1 reading has the potential to be distorted by statistical base effects. Overall, it will take some time for a rebound in the non-farm payroll sector to take place.
The USD-ZAR gapped higher in intraday trade yesterday as harsher domestic restrictions announced the previous evening weighed on the local unit. This was met with broadly weaker EM and major currencies as the greenback began the week on the front foot ahead of crucial US employment data later in the week. Still, the ZAR was hardest hit on account of third-wave risks currently being realised, which will undoubtedly impact the country’s growth and recovery prospects. As a result, the local currency weakened the most in the EM basket of currencies, losing 0.65% against the USD to close just shy of 14.2400/$.
The BER consumer confidence index equally weighed on sentiment towards the ZAR yesterday. The index declined in the Q2 print, erasing this year’s earlier gains, which saw it return to pre-pandemic levels. The ending of the social welfare payments and temporary relief measures for workers, the emergence of a third wave of infections, rising food and fuel prices all dented sentiment in Q2.
With the general market focus now falling towards monetary policy tightening and rate hikes, albeit still some time away, South Africa’s environment of subdued consumer and business confidence suggests that rate hikes too soon could derail the progress until now. However, a somewhat hawkish move can be noted by SARB governor Lesetja Kganyago yesterday after he stated there is a “compelling case” for lowering the reserve bank’s target inflation range. With inflationary pressures expected to remain muted, there is a definite possibility we see lower inflation targets coming up for discussion.
The Constitutional Court made an announcement yesterday that today at 10 am SA time, judgement will be handed down on ex-president Jacob Zuma’s contempt of court hearing in the state capture probe. If there is a guilty finding, sentencing will be the next step, with the recommendation being a two-year jail sentence. It is possible that the judgement is suspended on the condition that Zuma comply with the court, as a means of negotiation.
While his counterclaims are serious, Zuma has failed to show up for questioning and has not followed due process. Zuma has sat in open defiance of court orders and requests, calling into question the commission's integrity and suggesting bias in the process. Many have suggested that these are essentially Stalingrad tactics intended to reduce the effectiveness of the investigation for which he could face further jail time. The verdict today will therefore cause some major shifts in SA’s political fabric. That SA’s courts continue to process the corrupt is an encouraging factor for many investors and will maintain the impression that the government is cleaning up its act.
October elections are just a few months away. Following a very tough time for the SA economy and clear bungling of COVID response by the government that is still trying to find out how much of its COVID relief bill was looted, national government will need to demonstrate a clear desire for deep sweeping reforms or it will continue to hollow out its tax and voter base.
30 June 2021
7 reading min
Taking Stock - Walmart unveils low-price insulin.
In todays taking stock, we discuss how Walmart unveils low-price insulin as more patients with diabetes struggle to pay for drug.
©2019 Sasfin. All right reserved. Financial Services Provider (FSP) 23833 and Registered Credit Provider NCRCP22